|Day Low/High||4.90 / 5.15|
|52 Wk Low/High||4.75 / 7.54|
ASTRO Selects the Data for Center Stage at Largest Annual Meeting of Radiation Oncologists
Innovations in Hardware and Software Solutions and New Clinical Data Reinforce the Benefits of Accuray Systems in Treating a Wide Range of Cancer Cases
Accuray (ARAY) reported a larger-than-anticipated loss for the 2016 fiscal fourth quarter and a downbeat forecast following Wednesday's closing bell.
Accuray (ARAY) posted a wider-than-expected loss for the 2016 fiscal fourth quarter after Wednesday's market close.
Next Generation Image-Guided Radiation Therapy Platform and Integrated Software Solutions are Now Available for Use by Clinicians in the European Union
Clinical Research on the CyberKnife® System, Including the Multileaf Collimator, Presented at Leading Scientific Meeting for Medical Physicists
Clinical Research Also Showcases Innovative Approaches to Expanding TomoTherapy Platform Functionality
Here's a technical look at how to trade five biotech stocks that are setting up to break out and trade much higher.
Next Generation "Smart" System Enables Clinicians to Provide Highly Precise Treatment, Efficiently, for More Patients, Every Day
System Dedicated Solely to Breast Cancer Care Provides Excellent Clinical Outcomes
Largest Ever Accuray Deal Will Provide More Cancer Patients in the United Kingdom (UK) Access to Advanced, Precise Radiation Treatments
Investors considering a purchase of Accuray Inc shares, but tentative about paying the going market price of $5.30/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $5 strike, which has a bid at the time of this writing of 40 cents.
Collaboration Designed to Expand Clinical Versatility of the CyberKnife® System with Addition of medPhoton Novel Imaging Solution
Leading Oncology Specialists Discuss Best Practices and Innovations in Cancer Treatment
Trade-Ideas LLC identified Accuray (ARAY) as a strong on high relative volume candidate
Patients Benefit from Fewer Treatment Sessions and Minimal Side Effects
Investors eyeing a purchase of Accuray Inc stock, but tentative about paying the going market price of $5.03/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $4 strike, which has a bid at the time of this writing of 25 cents.
Premier Qatar, Latvian Cancer Centers to Offer Patients Treatment with the CyberKnife® System; Leading Bulgarian Hospital to Provide Treatment with the TomoTherapy® System
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
In trading on Thursday, shares of Accuray Inc crossed above their 200 day moving average of $6.96, changing hands as high as $7.13 per share. Accuray Inc shares are currently trading up about 3.2% on the day.